MUSC startup's SphynxVision brings real-time imaging to cancer research

MUSC startup OncoBLAZE is developing SphynxVision, a fluorescence imaging system that lets cancer researchers track experiments in real time under normal room lighting, unlike conventional dark-chamber systems. The technology aims to reveal biological changes current imaging misses. Created by Hollings researcher Dieter Haemmerich, SphynxVision uses a light source about 100 times brighter than standard systems and specialized image processing to filter room light interference. It captures multiple images per second with high resolution, allowing researchers to watch drug delivery, surgeries, and tissue responses as they happen. OncoBLAZE will unveil SphynxVision at the World Molecular Imaging Congress in September and recruit four or five laboratories for its Pioneer Program to test early versions. The technology grew from Haemmerich's chemotherapy research and received federal funding from NIH, NSF, and South Carolina Research Authority.